Research programme: radioisotope-based cancer therapeutics - Oncoinvent

Drug Profile

Research programme: radioisotope-based cancer therapeutics - Oncoinvent

Alternative Names: Radspherin®

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncoinvent
  • Class Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Peritoneal cancer

Most Recent Events

  • 13 Apr 2018 Oncoinvent plans phase I trials for Radspherin® in Peritoneal carcinomatosis by early 2019
  • 13 Apr 2018 Oncoinvent selects medicinal product regulatory pathway for Radspherin® in USA and Europe
  • 15 Nov 2017 Oncoinvent has patent protection for Radspherin® in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top